Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Avian InfluenzaH1N1 InfluenzaInfluenza

Phase 2

Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations

CompletedNCT02100436

National Institute of Allergy and Infectious Diseases (NIAID)Influenza

Start: 2014-06-11End: 2015-03-20Updated: 2017-07-06

H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses

CompletedNCT02921997

National Institute of Allergy and Infectious Diseases (NIAID)Avian Influenza, H1N1 Influenza, Influenza

Start: 2016-11-07End: 2018-02-14Updated: 2024-10-09

Related Papers

Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents.

2019-07-305 citations